Affordable Access

Access to the full text

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma

Authors
  • Su, Dan1
  • Wu, Bin2
  • Shi, Lizheng3
  • 1 Department of Pharmacy, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China
  • 2 dicine, Shanghai, China
  • 3 Department of Global Health Management and Policy, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana
Type
Published Article
Journal
JAMA Network Open
Publisher
American Medical Association
Publication Date
Feb 24, 2021
Volume
4
Issue
2
Identifiers
DOI: 10.1001/jamanetworkopen.2021.0037
PMID: 33625508
PMCID: PMC7905498
Source
PubMed Central
License
Green
External links

Abstract

This economic evaluation study using a partitioned survival model assesses whether atezolizumab plus bevacizumab is cost-effective compared with sorafenib for first-line treatment of unresectable hepatocellular carcinoma.

Report this publication

Statistics

Seen <100 times